Astellas Pharma Inc 4503
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4503 is a good fit for your portfolio.
News
-
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
-
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
-
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
-
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
-
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
-
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
-
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
Trading Information
- Previous Close Price
- JPY 1,469.00
- Day Range
- JPY 1,453.00–1,484.50
- 52-Week Range
- JPY 1,426.00–2,360.50
- Bid/Ask
- JPY 1,452.50 / JPY 1,455.50
- Market Cap
- JPY 2.61 Tril
- Volume/Avg
- 8.3 Mil / 9.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 16.56
- Price/Sales
- 1.72
- Dividend Yield (Trailing)
- 4.74%
- Dividend Yield (Forward)
- 4.74%
- Total Yield
- 7.07%
Company Profile
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 14,484
- Website
- http://www.astellas.com
Comparables
Valuation
|
Metric
|
4503
|
4568
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.56 | 41.33 | 27.16 |
Price/Book Value | 1.75 | 5.64 | 5.21 |
Price/Sales | 1.72 | 5.95 | 8.18 |
Price/Cash Flow | 9.48 | 32.26 | 25.50 |
Price/Earnings
4503
4568
4519
Financial Strength
|
Metric
|
4503
|
4568
|
4519
|
|---|---|---|---|
Quick Ratio | 0.69 | 2.74 | 3.68 |
Current Ratio | 0.91 | 3.49 | 4.74 |
Interest Coverage | 2.62 | 11.76 | 16,438.81 |
Quick Ratio
4503
4568
4519
Profitability
|
Metric
|
4503
|
4568
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | 1.82% | 7.33% | 17.64% |
Return on Equity (Normalized) | 3.43% | 13.01% | 21.60% |
Return on Invested Capital (Normalized) | 2.54% | 11.32% | 21.60% |
Return on Assets
4503
4568
4519
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Kvwpchfqc | Tpcxc | $696.2 Bil | |
JNJ
| Johnson & Johnson | Rbmbzwff | Nynzj | $357.9 Bil | |
MRK
| Merck & Co Inc | Fbvblvfq | Xsmfk | $321.5 Bil | |
ABBV
| AbbVie Inc | Qlwsgrsc | Ksm | $297.3 Bil | |
AZN
| AstraZeneca PLC ADR | Rmcywvqkqz | Bzwm | $219.1 Bil | |
NVS
| Novartis AG ADR | Wrfqfzdkr | Vmnhq | $199.4 Bil | |
RHHBY
| Roche Holding AG ADR | Nvbdjsmhb | Qchn | $196.3 Bil | |
PFE
| Pfizer Inc | Pwknkrvsy | Dgc | $148.7 Bil | |
AMGN
| Amgen Inc | Qyytvbmk | Tkrp | $146.4 Bil | |
SNY
| Sanofi SA ADR | Llztwcq | Pmcph | $117.2 Bil |